BioCentury
ARTICLE | Company News

Igenica, AstraZeneca deal

December 14, 2015 8:00 AM UTC

Igenica partnered with AstraZeneca’s MedImmune LLC unit to evaluate antibody-drug conjugates (ADCs) targeting surface antigen in leukemia (SAIL). Igenica will contribute its anti-SAIL antibodies, including IGN786, and its SNAP ADC drug linker technology. MedImmune will provide its pyrrolobenzodiazepine anti-tumor payload, and the companies will jointly investigate the resulting ADCs in preclinical studies.

MedImmune will also receive an option to gain an exclusive, worldwide license to anti-SAIL antibodies and ADCs resulting from the deal. Igenica will receive an option exclusivity fee. Upon exercise, Igenica will receive an undisclosed upfront payment and will be eligible for undisclosed clinical, regulatory and commercial milestones, plus undisclosed royalties. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article